Drug Trial Radar · NCT06829771
Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
Last checked: Nov 19, 2026Latest source record: Jan 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Apr 23, 2025
Primary completion
May 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To explore the efficacy and safety of TQB2825 injection combined immunochemotherapy in subjects with untreated or R/R DLBCL. The efficacy evaluation indicators are objective response rate (ORR), complete response rate (CR rate),progression free survival (PFS), duration of response (DOR) and overall survival(OS). The safety evaluation indicators are dose-limiting toxicity (DLT) , maximum tolerated dose (MTD)and recommended phase II dose (RP2D).
Conditions
- Diffuse Large B Cell Lymphoma
Interventions
TQB2825 injection +R-CHOP regimenDrug
R-CHOP is a cancer treatment regimen that uses a combination of five drugs to treat non-Hodgkin lymphoma, e.g., Rituximab+Cyclophosphamide+Doxorubicin Hydrochloride+Vincristine+Prednisone (R-CHOP). TQB2825 Injection: TQB2825 is a bispecific antibody targeting the cluster of differentiation 20 (CD20) receptor on tumor cells and the cluster of differentiation 3 (CD3) receptor on T cells. Rituximab: A monoclonal antibody that binds to the CD20 antigen on the surface of B cells. Cyclophosphamide: An alkylating agent that inhibits the synthesis of DNA and proteins in cancer cells. Doxorubicin Hydrochloride: An antineoplastic antibiotic that inhibits the synthesis of DNA and RNA. Vincristine: A microtubule inhibitor that blocks the normal function of microtubules during cell division. Prednisone: A corticosteroid drug with anti-inflammatory, anti-allergic, immunosuppressive, and anti-cancer effects. TQB2825 injection + GemOx (Gemcitabine + Oxaliplatin)
TQB2825 injection + GemOxDrug
TQB2825 Injection: TQB2825 is a bispecific antibody targeting the CD20 receptor on tumor cells and the CD3 receptor on T cells. Gemcitabine: A nucleoside analog that inhibits DNA synthesis. Oxaliplatin: A platinum-based chemotherapy drug that forms cross-links with DNA, inhibiting DNA replication and transcription.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Limited ToxicityTime frame: Baseline to up to two years
- Maximum tolerated dose (MTD)Time frame: Baseline to up to two years
Locations
25 sites in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Bengbu Medical College
Bengbu, Anhui, China · Not yet recruiting
Maanshan People's Hospital
Ma’anshan, Anhui, China · Recruiting
Beijing Cancer Hospital
Beijing, Beijing Municipality, China · Recruiting
Fujian Cancer Hospital
Fuzhou, Fujian, China · Not yet recruiting
The Second Affiliated Hospital of Fujian Medical University
Quanzhou, Fujian, China · Recruiting
Gansu Provincial Cancer Hospital
Lanzhou, Gansu, China · Not yet recruiting
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Not yet recruiting
Liuzhou People's Hospital
Liuzhou, Guangxi, China · Not yet recruiting
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China · Not yet recruiting
Puyang Oilfield General Hospital
Puyang, Henan, China · Not yet recruiting
Henan Cancer Hospital Affiliated Cancer Hospital of Zhengzhou University
Zhengzhou, Henan, China · Recruiting
Hubei Cancer Hospital
Wuhan, Hubei, China · Not yet recruiting
Jiangsu Provincial People's Hospital
Nanjing, Jiangsu, China · Not yet recruiting
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, China · Not yet recruiting
Jiangxi Canser Hospital
Nanchang, Jiangxi, China · Not yet recruiting
The First Hospital of Jilin University
Changchun, Jilin, China · Not yet recruiting
The second Hospital of dalian
Dalian, Liaoning, China · Not yet recruiting
Affiliated Cancer Hospital of Shandong First Medical University
Jinan, Shandong, China · Not yet recruiting
Yantai Yuhuangding Hospital
Yantai, Shandong, China · Not yet recruiting
Fudan university shanghai cancer center
Shanghai, Shanghai Municipality, China · Not yet recruiting
The First Affiliated Hospital of Xi'an Jiao Tong University
Xi'an, Shannxi, China · Not yet recruiting
Shanxi Cancer hospital
Taiyuan, Shanxi, China · Not yet recruiting
The Affiliated Hospital of Southwest Medical University
Luzhou, Sichuan, China · Not yet recruiting
People's Hospital of Tianjin (City)
Tianjin, Tianjin Municipality, China · Not yet recruiting
Tianjin Medical University Cancer Hospital
Tianjin, Tianjin Municipality, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.